Sir, I presume that the actual prevalence of group B streptococcus (GBS) meningitis is higher than 16% reported by Chauhan et al. [1] This is based on the presence of an important methodological limitation. Chauhan et al., [1] stated in their interesting study that 92.5% had received prior antibiotic treatment from some peripheral institutions before being referred to the tertiary care hospital. The gram staining and culture reports were negative in all their studied cases. Moreover, polymerase chain reaction (PCR) was not available for GBS. Ultimately, Chauhan et al., [1] totally relied upon latex particle agglutination test (LPAT) to establish the diagnosis of GBS meningitis in their studied cohort. It is worthy to mention that the sensitivity and specificity of LPAT has been found to be 66.66 and 87.91%, respectively. [2] Moreover, gram staining and LPAT could detect 85% of cases of acute bacterial meningitis (ABM). [3] With the combination of gram staining, culture, and LPAT; 100% sensitivity and specificity could be achieved and they are more productive than any single test. [2, 3] With the history of prior antibiotic administration, real-time PCR assay remains superior and the golden standard to firm diagnosis of ABM. [4] Considering that limitation, I presume that the actual magnitude of GBS meningitis was underestimated. Despite that limitation, Chauhan et al.,'s study [1] highlighted the importance of ongoing surveillance of GBS and triggered the need to delineate molecular characterization of GBS strains that might have implications for vaccine development strategies. With the absence of effective GBS vaccine currently, the protocol of universal culture-based screening at 35-37 weeks gestational age and intrapartum antimicrobial prophylaxis for GBS-colonized women has been recently proved in view of US experience to comprise a highly effective strategy to decrease the burden of subsequent infants' GBS infections. [5] The implementation of such protocol need to be considered in India. acid (GABA) modulation, high-voltage-gated N-type Ca2 + channel currents, and GABA release. [1] There are no known interactions between LEV and any other drug. Adverse effects include somnolence, and behavioral changes are usually mild to moderate. We report urinary and fecal incontinence not related to seizures in a child treated with LEV.
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A 11-year-old boy presented with a history of urinary and fecal incontinence since last 10 days to our hospital. He was born of an uneventful full-term pregnancy. Developmental milestones were normal. On medical history, he had nocturnal isolated seizures, followed by a postictal motor deficit at the right arm since 1 month. The electroencephalography (EEG) showed a normal background activity with spikes in the bilateral centrotemporal area. LEV had started 10 mg/kg/day, but several brief partial seizures were continued. The dose was increased to 20 mg/kg/day (500 mg/day), and his seizures were stopped. Three weeks after starting LEV therapy, he experienced daily urinary and fecal incontinence. On his examination, the vital signs, including the blood pressure were normal. His height and weight were normal limit for his age. The physical and neurological examination were unremarkable. There was no evidence of urinary tract and gastrointestinal infection.
On laboratory examination, routine hematological, biochemical analyzes, the urine and stool analysis were normal. A magnetic resonance imaging (MRI) scan of his lumbosacral spine and brain was showed as normal. In control EEG, we did not find non-convulsive status epilepticus.
We thought LEV may be the cause of his complaints and stopped LEV therapy. His urinary and fecal incontinence had completely resolved after discontinuation of LEV.
LEV is one of the new generation AED with an acceptable side effect profile used for preventing seizures. LEV has a different molecular structure from other new AEDs, does not bind to plasma proteins, and is eliminated by the kidneys. It has been argued that LEV can act on the N-type Ca 2+ channel and can reverse the GABA and glycine-gated currents.
[1] Fatigue, somnolence, behavioral problems and headache are among known side effects of LEV.
In the literature, there have been few reports of urinary and fecal incontinence induced by AEDs. [2] [3] [4] Gil-Nagel et al., [2] reported a 43-year-old man with mental retardation and epilepsy in whom fecal and bladder incontinence induced by gabapentin. The other case described by Iyer et al. [5] They described a 65-year-old woman with neuropathic pain. These cases illustrates that gabapentin can cause both urinary and fecal incontinence. Gil-Nagel et al., [2] hypothesized that incontinence was thought to be related to an effect of gabapentin in the cortex, interfering with the frontal lobe inhibition of the micturition center in the pons by modulation of neurotransmitters GABA and glutamate. Sandyk reported urinary incontinence associated with clonazepam therapy in a case. [3] In another case, Anders et al., [4] reported case of urinary incontinence due to carbamazepine treatment. We reported a 11-year-old boy with urinary and fecal incontinence during LEV therapy. To our knowledge, this is the first report of urinary and fecal incontinence induced by LEV therapy in the literature. There was no evidence of urinary and gastoinintestinal tract infection, and no evidence central nervous system involvement in our patient. Therefore, we thought the cause of his complaints due to LEV therapy. The exact urinary and fecal incontinence mechanism of LEV is unknown.
In conclusion, we conclude that LEV may cause urinary and fecal incontinence, however these effects are reversible. In clinical placebo controlled trials some adverse event may not be more frequent in the study drug group, post marketing experiences can sometimes discover new effects and side effects. The fact that the incontinence improved completely after drug withdrawal supports the ascribability hypothesis.
Children treated with LEV should be warned regarding these potential adverse effects, to facilitate early withdrawal of drug.
Faruk Incecik, Ozlem M. Herguner, Seyda Besen, Sakir Altunbasak
Department of Pediatric Neurology, Cukurova University Faculty of Medicine, Adana, Turkey
